Cara Therapeutics Inc CARA

Healthcare Cannabis

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

NDAQ:CARA - Post by User

Cara Therapeutics Inc

Bullboard Posts

Comment by pienteron Jul 31, 2018 2:44pm

177 Views

Post# 28393104

RE:CARA Leading Indicators

New here, so I can ask a stupid question, the forum here is hardly used, is CARA a recent introduction, or just unknown?Painkillers with no side effects, anti-itch medication that actually does not have a cure for it. FDA can provide surprises here. And then I come across this list of Chris on the forum of yahoo, for which I thanks Chris; PS I have not checked this data. Fresenius buys Liberty Dialysis for 2.1 Billion Fresenius buys Fenwell Holdings for 1.1 Billion Fresenius buys Akorn for 4.3 Billion Fresenius buys Rhoen Kunikun for 4.0 Billion Fresenius buys Nxstage for 2.0 Billion Fresenius to buy Quironsalud for 6.4 Billion Fresenius to buy APP Pharma for 3.7 Billion

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023